Corneal Neovascularization Clinical Trial
Official title:
Topical/Subconjunctival Injection of Bevacizumab(Avastin) for the Treatment of Corneal Neovascularization
The purpose of the current study is to assess the efficacy and safety of the inhibitory effect of bevacizumab (Avastin) with different routes including topical and subconjunctival application on corneal neovascularization in the human eyes.
The compassionate off-label use of bevacizumab as well as the potential risks, benefits, and adverse effects of this medication are discussed extensively with each patient. To further minimize systemic absorption, silicone punctual plugs are placed in the lower eyelids. One group of patients apply topical bevacizumab, 1.0%(10mg/ml), 4 times of day. The other group of patients received subconjunctival injection of bevacizumab(2.5mg/0.1ml) once. The patients are examined at 1day, 1week, 2weeks, 3weeks, and 1month, then monthly till the corneal neovascularization are gone or reduced to some degrees. Best-corrected visual acuity, slip-lamp examination, tonometry, external photography, pachymetry, specular microscopy (if possible), and systemic blood pressure are completed at all visits. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00555594 -
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
|
Phase 2/Phase 3 | |
| Completed |
NCT00004430 -
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
|
N/A | |
| Completed |
NCT00769145 -
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
|
Phase 1 | |
| Completed |
NCT01257750 -
Treatment of Corneal Neovascularization With Topical Pazopanib
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04787471 -
Corneal Crosslinking for Treatment of Corneal Neovascularization
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
| Withdrawn |
NCT00515684 -
Corneal Thinning During Topical Bevacizumab Therapy
|
N/A | |
| Terminated |
NCT02797704 -
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
| Terminated |
NCT01868360 -
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
|
Phase 1 | |
| Withdrawn |
NCT02042027 -
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
|
Phase 1 | |
| Recruiting |
NCT04215393 -
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
|
Phase 1 | |
| Completed |
NCT00797303 -
The Effect of Bevacizumab on Corneal Neovascularization
|
Phase 4 | |
| Recruiting |
NCT05659940 -
Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
|
||
| Completed |
NCT00559936 -
Topical Avastin for Treatment of Corneal Neovascularization
|
Phase 1 | |
| Completed |
NCT01072357 -
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04620109 -
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
|
Phase 1 | |
| Completed |
NCT00512876 -
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
|
N/A | |
| Recruiting |
NCT05011916 -
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
| Completed |
NCT01996826 -
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
| Terminated |
NCT00915590 -
Topical IL-1-Ra for Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 |